| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $103,616,650 | 5 | 100 |
Sells | $0 | 0 | 0 |
| DUGGAN ROBERT W | Co-Chief Executive Officer | 2 | $51.45M | 0 | $0 | $51.45M |
| Zanganeh Mahkam | Co-Chief Executive Officer | 2 | $51.45M | 0 | $0 | $51.45M |
| Soni Manmeet Singh | COO and CFO | 1 | $722,250 | 0 | $0 | $722,250 |
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit …
Over the last 12 months, insiders at Summit Therapeutics Inc. have bought $103.62M and sold $0 worth of Summit Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Summit Therapeutics Inc. have bought $129.14M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: DUGGAN ROBERT W (Co-Chief Executive Officer) — $51.45M. Zanganeh Mahkam (Co-Chief Executive Officer) — $51.45M. Soni Manmeet Singh (COO and CFO) — $722,250.
The last purchase of 3,810,000 shares for transaction amount of $49.99M was made by Zanganeh Mahkam (Co‑Chief Executive Officer) on 2026‑06‑12.
| 2026-06-12 | Zanganeh Mahkam | Co-Chief Executive Officer | 3.81M 0.4929% | $13.12 | $49.99M | +7.78% | ||
| 2026-06-12 | DUGGAN ROBERT W | Co-Chief Executive Officer | 3.81M 0.4929% | $13.12 | $49.99M | +7.78% | ||
| 2026-06-04 | Zanganeh Mahkam | Co-Chief Executive Officer | 100,000 0.0125% | $14.60 | $1.46M | +0.20% | ||
| 2026-06-04 | DUGGAN ROBERT W | Co-Chief Executive Officer | 100,000 0.0125% | $14.60 | $1.46M | +0.20% | ||
| 2026-06-04 | Soni Manmeet Singh | COO and CFO | 50,000 0.0062% | $14.45 | $722,250 | +0.20% | ||
| 2025-10-21 | Xia Yu | director | 533,617 0.0719% | $18.74 | $10M | -11.63% | ||
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | 26,680 0.0036% | $18.74 | $499,983 | -11.63% | ||
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | 26,680 0.0036% | $18.74 | $499,983 | -11.63% | ||
| 2025-09-11 | Zanganeh Mahkam | Co-Chief Executive Officer | 5,000 0.0007% | $18.07 | $90,350 | -8.60% | ||
| 2025-09-11 | DUGGAN ROBERT W | Co-Chief Executive Officer | 5,000 0.0007% | $18.07 | $90,350 | -8.60% | ||
| 2025-09-10 | Zanganeh Mahkam | Co-Chief Executive Officer | 333,394 0.0451% | $17.68 | $5.89M | -3.46% | ||
| 2025-09-10 | DUGGAN ROBERT W | Co-Chief Executive Officer | 333,394 0.0451% | $17.68 | $5.89M | -3.46% | ||
| 2024-03-27 | Zanganeh Mahkam | Chief Executive Officer | 80,321 0.0113% | $3.72 | $298,594 | +378.13% | ||
| 2024-03-26 | Dhingra Ankur | Chief Financial Officer | 100,000 0.0143% | $3.75 | $375,000 | +378.07% | ||
| 2024-03-26 | Zanganeh Mahkam | Chief Executive Officer | 30,000 0.0043% | $3.75 | $112,500 | +378.07% | ||
| 2023-12-13 | Dhingra Ankur | Chief Financial Officer | 20,400 0.0027% | $2.17 | $44,254 | +236.97% | ||
| 2023-12-12 | Zanganeh Mahkam | Chief Executive Officer | 5,000 0.0007% | $2.07 | $10,350 | +257.05% | ||
| 2023-10-13 | Soni Manmeet Singh | Chief Operating Officer | 2.98M 0.4265% | $1.68 | $5M | +163.99% | ||
| 2023-03-08 | Zanganeh Mahkam | Co-CEO & President | 23.53M 4.2977% | $1.05 | $24.7M | +26.97% | ||
| 2023-03-07 | Dhingra Ankur | Chief Financial Officer | 196,362 0.0395% | $1.05 | $206,180 | +39.86% |
| DUGGAN ROBERT W | Co-Chief Executive Officer | 573883879 71.9378% | $9.07B | 9 | 0 | +24.03% |
| Zanganeh Mahkam | Co-Chief Executive Officer | 573883879 71.9378% | $9.07B | 11 | 0 | +120.05% |
| Soni Manmeet Singh | COO and CFO | 3123603 0.3916% | $49.35M | 2 | 0 | +163.99% |
| Xia Yu | director | 32057147 4.0184% | $506.5M | 1 | 0 | <0.0001% |
| Dhingra Ankur | Chief Financial Officer | 354958 0.0445% | $5.61M | 4 | 0 | +181.3% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B |
| Increased Positions | 113 | +39.51% | 22M | +21.05% |
| Decreased Positions | 127 | -44.41% | 8M | -7.86% |
| New Positions | 36 | New | 1M | New |
| Sold Out Positions | 59 | Sold Out | 4M | Sold Out |
| Total Postitions | 272 | -4.9% | 118M | +13.19% |
| Baker Bros. Advisors Lp | $590,827.00 | 4.53% | 33.72M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $199,373.00 | 1.53% | 11.38M | +3M | +31.2% | 2025-09-30 |
| Fmr Llc | $156,241.00 | 1.2% | 8.92M | -308,489 | -3.34% | 2025-09-30 |
| Blackrock, Inc. | $129,014.00 | 0.99% | 7.36M | +517,126 | +7.55% | 2025-09-30 |
| State Street Corp | $111,461.00 | 0.86% | 6.36M | +2M | +58.35% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $79,520.00 | 0.61% | 4.54M | +633,675 | +16.23% | 2025-09-30 |
| Geode Capital Management, Llc | $54,886.00 | 0.42% | 3.13M | +197,920 | +6.74% | 2025-09-30 |
| Morgan Stanley | $33,758.00 | 0.26% | 1.93M | +1M | +200.13% | 2025-09-30 |
| Pictet Asset Management Holding Sa | $28,105.00 | 0.22% | 1.6M | -559,710 | -25.87% | 2025-09-30 |
| Norges Bank | $24,350.00 | 0.19% | 1.39M | +1M | +1,289.86% | 2025-06-30 |